Protein extracts from Momordica charantia var. charantia and M. charantia var. muricata show anti-lipidemic and antioxidant properties in experimental type 2 diabetic rats.

Plant-derived compounds are used to manage dyslipidemia and oxidative stress in type 2 diabetic condition. In this study, anti-lipidemic and antioxidant properties of the protein extracts from "Charantia" (PEC) and "Muricata" (PEM) varieties of Momordica charantia were analyzed by quantifying lipids, hepatic, renal, and oxidative stress markers, and histopathological examination of liver and kidney tissues. Protein extracts were orally administered at 10 (PEC10, PEM10) or 20 mg/kg body weight (PEC20, PEM20). Levels of cholesterol, low-density lipoprotein, and triglycerides decreased but high-density lipoprotein increased significantly in treated rats as compared to untreated diabetic rats (p < .01), and attained normal physiological range in both doses. Levels of superoxide dismutase, catalase, glutathione peroxidase, and reduced glutathione increased but thiobarbituric acid reactive substances decreased significantly in treated rats as compared to untreated diabetic rats (p < .01), and attained normal physiological range in PEM20 only. Histopathological examinations supported a protective role for the protein extracts against oxidative stress. PRACTICAL APPLICATIONS: Momordica charantia, a well-known medicinal plant is traditionally used for treating diabetes in India as well as other countries. The whole plant was shown to have medicinal importance. Anti-diabetic potential of this plant was scientifically established largely using organic extracts and water extract mainly from the fruits of this plant. However, protein extracts from the seeds and fruit pulp of this plant were also proven to have anti-diabetic activity. The present study illustrates the anti-lipidemic and antioxidant effect of protein extracts from the fruit pulp of two varieties of M. charantia (Charantia and Muricata) in Streptozotocin-induced type 2 diabetic rats. This study provides experimental evidence in support of its use in the management of type 2 diabetes-related complications.